JOURNAL OF CLINICAL INVESTIGATION-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2025-06-27 ms5000000738743687 来自四川省

偏重的研究方向：免疫;炎症;药理
经验分享：6.10投稿，目前在编辑手里

9 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2024-10-19 GISL 来自重庆

救命，20天了还在 Under consideration by Editorial Board

66 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2023-10-04 ms1000000589600011 来自瑞典

审稿速度:2.0
偏重的研究方向：免疫;肿瘤
经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验

184 5 举报

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2025-04-03 shawnfang 来自广东省

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：神经科学
经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。

22 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2025-03-18 ms1000000226329121 来自北京

审稿速度:1.0 | 投稿命中率:5.0
偏重的研究方向：细胞生物学
经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给

25 0 举报

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2024-07-02 ms1000002046808533 来自广东省

审稿速度:1.0 | 投稿命中率:25.0
经验分享：一篇正在under consideration by editorial board

121 4 举报

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2024-05-29 ms1000000131596023 来自山东省

请问大家 Under consideration by Editorial Board大概多长时间？

145 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2019-05-29 bigapple001

投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表::
投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表:
投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。

drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。

312 3 举报

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2024-06-29 Charlo 来自安徽省

偏重的研究方向：医学;分子机制
经验分享：Under consideration by Editorial Board 两周了还没动静没动静

129 2 举报

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2271044, encodeId=87a222e104442, content=偏重的研究方向：免疫;炎症;药理 经验分享：6.10投稿，目前在编辑手里, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/e8b5235f7abb4bcf90f5b2245264c95a-jim6YUjGO9EG.jpg, createdBy=cb276420537, createdName=ms5000000738743687, createdTime=Fri Jun 27 10:13:18 CST 2025, time=2025-06-27, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2231650, encodeId=88882231650e2, content=救命，20天了还在 Under consideration by Editorial Board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/03/388106d423117cc1168724c51b80fa15.jpg, createdBy=c6ad5233418, createdName=GISL, createdTime=Sat Oct 19 00:23:40 CST 2024, time=2024-10-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2160829, encodeId=3b9b2160829dc, content=审稿速度:2.0 偏重的研究方向：免疫;肿瘤 经验分享：回报本版，提供两篇文章的时间线。总的来说感觉编辑很有效率，各种沟通都很顺畅。第一篇已经发表 20220418 提交 20220421 editorial review 20220425 external peer review 20220509 status modified 20220516 major revision。两个审稿人 20221207 修回稿提交几次status modified之后在12月30号接收。第二篇在修回 20230829 提交，当天under consideration 20230831 外审 20230906 status modified 20230908 status modified 20230912 status modified 20230914 status modified 20231001 status modified 20231003 大修，三个评审。这一篇中间状态变了好多次，感觉可能是额外邀请了评审人。目前在补实验, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=184, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21c18135642, createdName=ms1000000589600011, createdTime=Wed Oct 04 04:58:18 CST 2023, time=2023-10-04, status=1, ipAttribution=瑞典), GetPortalCommentsPageByObjectIdResponse(id=2258960, encodeId=32ce225896065, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：神经科学 经验分享：投稿第一天，associate editor让我修改格式，第二天，转为under consideration by editoral board, 一个星期后拒稿。理由：稿件量大。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eo7ZPje2ZG8XdFTrM3dRGvtvzNHAB2PlicA2wv66YdDtw55hxsULCZLzicYSaNE0tRK59salhNA0xRw/132, createdBy=e5e52073583, createdName=shawnfang, createdTime=Thu Apr 03 14:34:49 CST 2025, time=2025-04-03, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2256595, encodeId=21a02256595fa, content=审稿速度:1.0 | 投稿命中率:5.0 偏重的研究方向：细胞生物学 经验分享：JCI好难，5天拒稿，没有送审。理由是他们每年接收超4000的稿件。标准拒稿信，啥意见也没给, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=d7cb5558800, createdName=ms1000000226329121, createdTime=Tue Mar 18 16:17:42 CST 2025, time=2025-03-18, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2212785, encodeId=77482212e85fa, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：一篇正在under consideration by editorial board, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=121, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=52cc8288395, createdName=ms1000002046808533, createdTime=Tue Jul 02 14:28:51 CST 2024, time=2024-07-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2207211, encodeId=a715220e211ef, content=请问大家 Under consideration by Editorial Board大概多长时间？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=16a16166362, createdName=ms1000000131596023, createdTime=Wed May 29 09:43:58 CST 2024, time=2024-05-29, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=571646, encodeId=9b7d5e1646d1, content=投稿有很大的随机性差杂志拒了发在好杂志上也是常见的事摆正心态drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。drCHD 2019-05-08 00:00:00 发表: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, beContent=drCHD 2019-05-08 发表:: 投JCI有非常不愉快的经历。二次投稿均是三天内秒拒，理由一样都说研究偏浅。后来二篇文章，都发表在IF相当甚至更高的杂志。所以JCI当编辑初筛有很大的随意性。我们一个研究做了二个大鼠敲除二个小鼠敲除一共四个模式动物都被编辑轻飘飘一句秒拒了，真很不服气。作为老牌杂志，真对其蛮有好感的，但十年来IF一直徘徊，被很多新锐杂志赶超 JCI真该反思啊。总而言之，以后不太会考虑此杂志。大家被秒拒也不要灰心，不要被草率的编辑打击自己的信心。, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f8eb1668018, createdName=bigapple001, createdTime=Wed May 29 00:00:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2212333, encodeId=cb66221233310, content=偏重的研究方向：医学;分子机制 经验分享：Under consideration by Editorial Board 两周了还没动静没动静, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=129, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202405/1b6a659c33ed41a19b3fc19abdc5b8f3-8OK9tR5oDTlo.jpg, createdBy=f0775421661, createdName=Charlo, createdTime=Sat Jun 29 13:16:50 CST 2024, time=2024-06-29, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2117169, encodeId=4e2f211e16978, content=请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=202, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a373249382, createdName=12cea5a4m34暂无昵称, createdTime=Thu Mar 02 09:07:19 CST 2023, time=2023-03-02, status=1, ipAttribution=广东省)]

2023-03-02 12cea5a4m34暂无昵称来自广东省

请问大家 Under consideration by Editorial Board时间久是不是说明没什么外审希望？感谢有经验的前辈回复~~

202 4 举报

展开4条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务